中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2012年
8期
817-820
,共4页
吴秀军%王艳蕾%张凤宇%张田%肖连英
吳秀軍%王豔蕾%張鳳宇%張田%肖連英
오수군%왕염뢰%장봉우%장전%초련영
慢性阻塞性肺疾病%七叶皂苷钠%氧化应激%肺功能
慢性阻塞性肺疾病%七葉皂苷鈉%氧化應激%肺功能
만성조새성폐질병%칠협조감납%양화응격%폐공능
Chronic obstructive pulmonary disease%Sodium aescinate%Oxidative stress%Lung function
目的 探讨七叶皂苷钠对慢性阻塞性肺疾病(COPD)急性加重期氧化应激和肺功能的影响.方法 120例符合COPD纳入标准的患者随机分为对照组60例和治疗组60例.所有患者均给予常规抗感染、吸氧、化痰和平喘等对症治疗,治疗组在常规对症治疗基础上加用七叶皂苷钠.两组均于治疗前及治疗后2周测定血清超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)以及总抗氧化能力(T-AOC),同时进行肺功能和6 min步行距离(6MWD)检测,并与60名健康体检者(健康组)进行比较.结果 治疗组总有效率91.67％(55/60),对照组总有效率76.67％(46/60),差异有统计学意义(x2=5.065,P＜0.05).治疗前对照组血清MDA(9.25±1.55) μmol/L和治疗组(9.74±1.50) μmol/L较健康组(2.06±0.29) μμmol/L高,差异均有统计学意义(P均＜0.001),而血清SOD[对照组(91.14 ±9.54) kU/L、治疗组(90.61±8.01) kU/L]、GSH-Px[对照组(139.38±36.56) U/L、治疗组(137.57±34.19) U/L]、T-AOC[对照组(6.48±1.15)kU/L、治疗组(6.39±1.13)kU/L]水平较健康组[(116.63±6.57)kU/L、(189.34±35.54) U/L、(13.34±1.23) kU/L]低,差异均有统计学意义(P均＜0.001).治疗后两组各指标较治疗前均有所改善(P＜0.001),但治疗后治疗组血清MDA[(4.56±1.39) μmol/L]与对照组[(5.85±1.37) μmol/L]比较明显下降,差异有统计学意义(t=6.517,P＜0.001),血清SOD[(103.85±7.07) kU/L]、GSH-Px[(169.65±34.51) U/L]、T-AOC[(10.52±1.09)kU/L]水平,第1秒用力呼气容积/用力肺活量(FEV1/FVC)[(60.49±6.11)％],FEV1占预计值％[(76.62±6.35)％]以及6MWD[(394.83±10.11)m]与对照组[分别为(97.99±6.24) kU/L、(156.33±38.31)U/L、(8.82±1.41)kU/L、(53.84±2.97)％、(67.86±4.58)％、(331.19±11.03)m]比较明显升高,差异有统计学意义(t值分别为6.574、2.738、7.137、6.574、6.517、21.198,P均＜0.001).结论 氧化应激参与了COPD急性加重期的病理生理过程,七叶皂苷钠可能通过减轻COPD急性加重期患者氧化应激水平改善肺功能.
目的 探討七葉皂苷鈉對慢性阻塞性肺疾病(COPD)急性加重期氧化應激和肺功能的影響.方法 120例符閤COPD納入標準的患者隨機分為對照組60例和治療組60例.所有患者均給予常規抗感染、吸氧、化痰和平喘等對癥治療,治療組在常規對癥治療基礎上加用七葉皂苷鈉.兩組均于治療前及治療後2週測定血清超氧化物歧化酶(SOD)、丙二醛(MDA)、穀胱甘肽過氧化物酶(GSH-Px)以及總抗氧化能力(T-AOC),同時進行肺功能和6 min步行距離(6MWD)檢測,併與60名健康體檢者(健康組)進行比較.結果 治療組總有效率91.67％(55/60),對照組總有效率76.67％(46/60),差異有統計學意義(x2=5.065,P＜0.05).治療前對照組血清MDA(9.25±1.55) μmol/L和治療組(9.74±1.50) μmol/L較健康組(2.06±0.29) μμmol/L高,差異均有統計學意義(P均＜0.001),而血清SOD[對照組(91.14 ±9.54) kU/L、治療組(90.61±8.01) kU/L]、GSH-Px[對照組(139.38±36.56) U/L、治療組(137.57±34.19) U/L]、T-AOC[對照組(6.48±1.15)kU/L、治療組(6.39±1.13)kU/L]水平較健康組[(116.63±6.57)kU/L、(189.34±35.54) U/L、(13.34±1.23) kU/L]低,差異均有統計學意義(P均＜0.001).治療後兩組各指標較治療前均有所改善(P＜0.001),但治療後治療組血清MDA[(4.56±1.39) μmol/L]與對照組[(5.85±1.37) μmol/L]比較明顯下降,差異有統計學意義(t=6.517,P＜0.001),血清SOD[(103.85±7.07) kU/L]、GSH-Px[(169.65±34.51) U/L]、T-AOC[(10.52±1.09)kU/L]水平,第1秒用力呼氣容積/用力肺活量(FEV1/FVC)[(60.49±6.11)％],FEV1佔預計值％[(76.62±6.35)％]以及6MWD[(394.83±10.11)m]與對照組[分彆為(97.99±6.24) kU/L、(156.33±38.31)U/L、(8.82±1.41)kU/L、(53.84±2.97)％、(67.86±4.58)％、(331.19±11.03)m]比較明顯升高,差異有統計學意義(t值分彆為6.574、2.738、7.137、6.574、6.517、21.198,P均＜0.001).結論 氧化應激參與瞭COPD急性加重期的病理生理過程,七葉皂苷鈉可能通過減輕COPD急性加重期患者氧化應激水平改善肺功能.
목적 탐토칠협조감납대만성조새성폐질병(COPD)급성가중기양화응격화폐공능적영향.방법 120례부합COPD납입표준적환자수궤분위대조조60례화치료조60례.소유환자균급여상규항감염、흡양、화담화평천등대증치료,치료조재상규대증치료기출상가용칠협조감납.량조균우치료전급치료후2주측정혈청초양화물기화매(SOD)、병이철(MDA)、곡광감태과양화물매(GSH-Px)이급총항양화능력(T-AOC),동시진행폐공능화6 min보행거리(6MWD)검측,병여60명건강체검자(건강조)진행비교.결과 치료조총유효솔91.67％(55/60),대조조총유효솔76.67％(46/60),차이유통계학의의(x2=5.065,P＜0.05).치료전대조조혈청MDA(9.25±1.55) μmol/L화치료조(9.74±1.50) μmol/L교건강조(2.06±0.29) μμmol/L고,차이균유통계학의의(P균＜0.001),이혈청SOD[대조조(91.14 ±9.54) kU/L、치료조(90.61±8.01) kU/L]、GSH-Px[대조조(139.38±36.56) U/L、치료조(137.57±34.19) U/L]、T-AOC[대조조(6.48±1.15)kU/L、치료조(6.39±1.13)kU/L]수평교건강조[(116.63±6.57)kU/L、(189.34±35.54) U/L、(13.34±1.23) kU/L]저,차이균유통계학의의(P균＜0.001).치료후량조각지표교치료전균유소개선(P＜0.001),단치료후치료조혈청MDA[(4.56±1.39) μmol/L]여대조조[(5.85±1.37) μmol/L]비교명현하강,차이유통계학의의(t=6.517,P＜0.001),혈청SOD[(103.85±7.07) kU/L]、GSH-Px[(169.65±34.51) U/L]、T-AOC[(10.52±1.09)kU/L]수평,제1초용력호기용적/용력폐활량(FEV1/FVC)[(60.49±6.11)％],FEV1점예계치％[(76.62±6.35)％]이급6MWD[(394.83±10.11)m]여대조조[분별위(97.99±6.24) kU/L、(156.33±38.31)U/L、(8.82±1.41)kU/L、(53.84±2.97)％、(67.86±4.58)％、(331.19±11.03)m]비교명현승고,차이유통계학의의(t치분별위6.574、2.738、7.137、6.574、6.517、21.198,P균＜0.001).결론 양화응격삼여료COPD급성가중기적병리생리과정,칠협조감납가능통과감경COPD급성가중기환자양화응격수평개선폐공능.
Objective To investigate the effects of sodium aescinate(SA)on oxidative stress and pulmonary function during acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods One hundred and twenty patients with COPD were randomly divided into two groups:the control group(n =60) and the treatment group(n =60).All patients were treated with routine anti-infection,oxygen inhalation,relieving phlegm and anti-asthma The treatment group took SA in addition to the routine beteropathy.The changes of serum SOD,MDA,GSH-Px,T-AOC,pulmonary functions and 6 minute walk distance(6MWD) were detected before and after two-week treatment in patients of the two groups to compare with 60 healthy subjects.Results The total effective rate in the treatment group was 91.67％,while 76.67％ in the control group.The difference was statistically significant(x2 =5.065,P ＜0.05).Serum MDA level in both groups were comparatively higher than the healthy controls(9.25±1.55) μmol/L vs.(9.74±1.50) μmol/L vs.(2.06±0.29) μmol/L,P ＜0.001),while the levels of SOD,GSH-Px and T-AOC were lower than the healthy controls[SOD:(91.14±9.54) kU/L vs.(90.61±8.01) kU/L vs.(116.63±6.57) kU/L; GSH-Px:(139.38±36.56) U vs.(137.57±34.19) U/L vs.(189.34±35.54) U/L; T-AOC:(6.48±1.15) kU/L vs.(6.39±1.13) kU/L vs.(13.34±1.23)kU/L;P < 0.001].After treatment,all indexes of the two groups were obviously ameliorated in comparison with before treatment(P ＜ 0.001),but the level of MDA[(4.56±1.39) μmol/L]in the treatment group decreased more greatly than in the control groups(P ＜ 0.001).The levels of SOD[(103.85±7.07) kU/L],GSH-Px[(169.65±34.51) U/L],T-AOC[(10.52±1.09) KU/L],forced expiratory volume in 1 second/forced vital capacity(FEV1/FVC)[(60.49±6.11)％],FEVI％[(76.62±6.35)％]and 6MWD [(394.83±10.11)m]increased considerably more than those in the control group(P ＜ 0.001).Conclusion Oxidative stress might be involved in the course of acute exacerbation of COPD.Sodium aeseinate can improve the pulmonary functions by ameliorating the oxidative stress during acute exacerbation in patients with COPD.
